Dyne Therapeutics (DYN) Cash from Investing Activities (2019 - 2026)

Dyne Therapeutics (DYN) has reported Cash from Investing Activities for 8 consecutive years, with -$4.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 170.79% year-over-year to -$4.8 million; the TTM figure through Jun 2026 stood at -$44.2 million (down 62.5% YoY), while the FY2025 annual figure was -$28.8 million, up 85.91% from the prior year.
• Cash from Investing Activities eased to -$4.8 million in Q2 2026 per DYN's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $51.7 million in Q3 2022 and bottomed at -$179.8 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$3.9 million across 5 years, with a median of $4.1 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 8285.96% — and 2024, when it plunged 764.54%.
• Dyne Therapeutics' Cash from Investing Activities stood at $19.2 million in 2022, then surged by 36.18% to $26.2 million in 2023, then tumbled by 161.12% to -$16.0 million in 2024, then jumped by 106.13% to $982000.0 in 2025, then plunged by 588.29% to -$4.8 million in 2026.
• Business Quant data shows DYN's Cash from Investing Activities at -$4.8 million in Q2 2026, -$2.4 million in Q1 2026, and $982000.0 in Q4 2025.